Real-World Success Stories: Infectious Insights

Discover how leading clinicians are using Vibativ® (telavancin) in real-world clinical settings to combat difficult-to-treat Gram-positive infections.1

The Infectious Insights series features short, focused video discussions and downloadable case studies that showcase the practical application of Vibativ in diverse care environments. These resources highlight real-world experiences in managing challenging infections such as MRSA, HABP/VABP, and complex cSSSIs, including those with suspected biofilm involvement.1,2 
 
Each case is driven by expert-led perspectives, offering firsthand insights from infectious disease specialists on the clinical use of Vibativ in managing difficult-to-treat infections.
1

A Case of Persistent Gram-Positive Bacterial Infection

Discover how Dr. Dold successfully treated a patient's persistent Gram-positive infection after initial therapies failed in this tough-to-treat case study.
Learn More >
2

A Case of Healthcare-Associated / Ventilator-Associated Bacterial Pneumonia (HABP/VABP)

See how Dr. Jacobs' timely intervention and clinical precision were vital in treating this ICU patient's MRSA pneumonia.
Learn More >
3

A Case of Complicated Skin and Skin Structure Infection (cSSSI)

Explore the full patient journey as Dr. Reilly used once-daily dosing to transition a complex skin infection case from acute care to outpatient therapy.
Learn More >

Clinical Value

Highlight Image
Delivers potent bactericidal activity against Gram-positive pathogens, including MRSA, with dual mechanism of action.1
Highlight Image (1)
Once-daily dosing with no therapeutic drug monitoring simplifies treatment for complex infections, including in obese patients.1
Highlight Image (2)
Reinforces timely escalation and the importance of reassessing therapy in non-resolving infections.3
Highlight Image (3)
Demonstrates efficacy in persistent Gram-positive bacterial infections.3
Case Study 1 - Video 1 Case Study 1 - Video 2 Case Study 1 - Video 3

Clinical Value

f8527f338bfdf3429e6ce316bfa806e2de81da7c
 Exhibits rapid and high tissue penetration into the epithelial lining fluid (ELF) and alveolar macrophages, and remains active in the presence of pulmonary surfactant.4
a96cfa942b8dce3f44afd79dc34c41aecb196cae
Reduced ICU stay, shorter hospitalization, and less ventilator time contributes to a favorable cost-benefit profile when compared to vancomycin in the critical care setting.5
aaa62b7a27d7ae8bd2c75571859344f00cb185a7 (1)
Once-daily IV dosing simplifies care in the ICU and eliminates the need for therapeutic drug monitoring.1
fba4249d90b2e63a99b5fc360b6dc44e5feba6e2
Indicated for HABP/VABP caused by Gram-positive organisms, including MRSA, demonstrating high cure rates in monomicrobial S. aureus infections compared to vancomycin.1
Case Study 2 - Video 1 (1) Case Study 2 - Video 2 Case Study 2 - Video 3

Clinical Value

74474e16d69a641f517903e40b1c9ff9b72715c7
Vibativ has been shown to penetrate and remain active against biofilm-forming MRSA, in both in vitro and animal models.6
e9d4ba975f885d64048fe8a8a3e39729ebe694cf
Clinical research supports Vibativ use in prosthetic joint infections and hardware-associated infections, which are often complicated by resistant pathogens.7,8
7b6450b17dfd8e874763a633cc3c331888f3cd15
Compatible in elastomeric pumps.9
c809ada254245c17a073c812e8880f5a36552d40
Effective treatment option for difficult-to-treat, post-surgical MRSA skin infections when vancomycin or other therapies have failed.2
7764d413abb170872a0b11bbccbe1b82a8ec794d
 Offers once-daily IV dosing with no therapeutic drug monitoring, ideal for transitioning to OPAT.1
254b2f6cbdc9ce82b5964bcdb10e244c33ced0d0
Demonstrates activity against complicated resistant pathogens, including MRSA.2
Case Study 3 - Video 1 Case Study 3 - Video 2 Case Study 3 - Video 3

These real-world cases show how Vibativ® delivers success when other treatments fall short, offering evidence-based insights and confidence in managing tough Gram-positive infections.

Want to know more about Vibativ?

Contact a Medical Science Liaison Today.
SPEAK TO MEDICAL LIAISON

See full prescribing information, including boxed warning. 

Vibativ (telavancin) Injection

INDICATION: Vibativ is indicated in adults for the treatment of:

  • complicated skin and skin structure infections (cSSSI) caused by susceptible isolates of the following Gram-positive microorganisms: Staphylococcus aureus (including methicillin-susceptible and -resistant isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus anginosus group (includes S. anginosus, S. intermedius, and S. constellatus), or Enterococcus faecalis (vancomycin-susceptible isolates only).
  • hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP), caused by susceptible isolates of Staphylococcus aureus (both methicillin-susceptible and -resistant isolates). Vibativ should be reserved for use when alternative treatments are not suitable.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Vibativ and other antibacterial drugs, Vibativ should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.

This product includes the following Boxed Warning:

WARNING: INCREASED MORTALITY IN HABP/VABP PATIENTS WITH PRE-EXISTING MODERATE OR SEVERE RENAL IMPAIRMENT, NEPHROTOXICITY, and EMBRYO-FETAL TOXICITY

Patients with pre-existing moderate/severe renal impairment (CrCl ≤50 mL/min) who were treated with VIBATIV for hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia had increased mortality observed versus vancomycin. Use of VIBATIV in patients with pre-existing moderate/severe renal impairment (CrCl ≤50 mL/min) should be considered only when the anticipated benefit to the patient outweighs the potential risk.

  • Nephrotoxicity: New onset or worsening renal impairment has occurred. Monitor renal function in all patients.
  • Embryo-Fetal Toxicity: VIBATIV may cause fetal harm. In animal reproduction studies, adverse developmental outcomes were observed in 3 animal species at clinically relevant doses. Verify pregnancy status prior to initiating treatment and advise females of reproductive potential to use effective contraception.


IMPORTANT DOSAGE AND ADMINISTRATION INSTRUCTIONS
Because telavancin is eliminated primarily by the kidney, a dosage adjustment is required for patients whose creatinine clearance is ≤50 mL/min. There is insufficient information to make specific dosage adjustment recommendations for patients with end-stage renal disease (CrCl <10 mL/min), including patients undergoing hemodialysis.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS
Vibativ should not be used with intravenous unfractionated heparin sodium because the activated partial thromboplastin time (aPTT) test results are expected to be artificially prolonged for 0 to 18 hours after Vibativ administration. Do not be use in patients with known hypersensitivity to Vibativ (telavancin).
 
WARNINGS AND PRECAUTIONS

  • Decreased efficacy among patients treated for cSSSI with moderate/severe pre-existing renal impairment. Consider when selecting antibacterial therapy for patients with baseline CrCl ≤50 mL/min.
  • Laboratory tests: interferes with some laboratory coagulation tests, including prothrombin time, international normalized ratio, and activated partial thromboplastin time.
  • Serious and potentially fatal hypersensitivity reactions, including anaphylactic reactions, may occur after first or subsequent doses. Use with caution in patients with known hypersensitivity to vancomycin.
  • Administer Vibativ over at least 60 minutes to minimize infusion-related reactions.
  • Clostridium difficile-Associated Diarrhea; may range from mild diarrhea to fatal colitis. Evaluate if diarrhea occurs.
  • Avoid use in patients at risk for QTc prolongation and who are taking drugs known to prolong the QT interval.

ADVERSE REACTIONS
The most common adverse reaction (≥10% of patients treated with Vibativ) in the HABP/VABP trials is diarrhea; in the cSSSI trials, the most common adverse reactions (≥10% of patients treated with Vibativ) include: taste disturbance, nausea, vomiting, and foamy urine.

USE IN SPECIAL POPULATIONS
Pediatric Use: Safety and efficacy have not been established. There is a concern for poor clinical outcomes in pediatric patients less than one year of age due to immature renal function.

References:

  1. Vibativ® [Package Insert]. Nashville, TN: Cumberland Pharmaceuticals; November 2023.
  2. Meeker, et al. Evaluation of Antibiotics Active against Methicillin-Resistant Staphylococcus aureus Based on Activity in an Established Biofilm. Antimicrob Agents Chemother. 2016; 60(10): 5688-94.
  3. Ruggero MA, et al. Telavancin for refractory methicillin-resistant Staphylococcus aureus bacteremia and infective endocarditis. Infectious Dis. 2015;1–6.
  4. Gotfried MH, et al. Intrapulmonary Distribution of Intravenous Telavancin in Healthy Subjects and Effect of Pulmonary Surfactant on In Vitro Activities of Telavancin and Other Antibiotics. Antimicrob Agents Chemother. 2008;52:92–97.
  5. McKinnell, et al. Effective Antimicrobial Stewardship Strategies for Cost-effective Utilization of Telavancin for the Treatment of Patients with Hospital-acquired Staphylococcus aureus. Clinical Ther. 2018; 40(3):406-414.e2.
  6. Chan C, et al. A review of telavancin activity in in-vitro biofilms and animal models of biofilm-associated infections. Future Microbiol. 2015;10(8):1325–1338.
  7. Jacqueline C, Caillon J. Impact of bacterial biofilm on the treatment of prosthetic joint infections. J Antimicrob Chemo. 2014;69 Suppl 1:i37–i40.
  8. Visperas A, et al. Current treatments for biofilm-associated periprosthetic joint infection and new potential strategies. J Orthop Res. 2022;40:1477–1491.
  9. Sand P, et al. Chemical Stability of Telavancin in Elastomeric Pumps. Curr Ther Res. 2015;77:99-104.

WWW1300625